- Home
- LPTX vs NTIP Comparison
LPTX vs NTIP Comparison
Compare LPTX & NTIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- NTIP
- Stock Information
- Founded
- LPTX 2011
- NTIP 1990
- Country
- LPTX United States
- NTIP United States
- Employees
- LPTX N/A
- NTIP N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- NTIP Multi-Sector Companies
- Sector
- LPTX Health Care
- NTIP Miscellaneous
- Exchange
- LPTX Nasdaq
- NTIP Nasdaq
- Market Cap
- LPTX 35.4M
- NTIP 32.0M
- IPO Year
- LPTX N/A
- NTIP 1998
- Fundamental
- Price
- LPTX $0.42
- NTIP $1.50
- Analyst Decision
- LPTX Hold
- NTIP
- Analyst Count
- LPTX 1
- NTIP 0
- Target Price
- LPTX N/A
- NTIP N/A
- AVG Volume (30 Days)
- LPTX 7.1M
- NTIP 8.8K
- Earning Date
- LPTX 11-13-2025
- NTIP 10-24-2025
- Dividend Yield
- LPTX N/A
- NTIP 6.67%
- EPS Growth
- LPTX N/A
- NTIP N/A
- EPS
- LPTX N/A
- NTIP N/A
- Revenue
- LPTX N/A
- NTIP $150,000.00
- Revenue This Year
- LPTX N/A
- NTIP N/A
- Revenue Next Year
- LPTX N/A
- NTIP N/A
- P/E Ratio
- LPTX N/A
- NTIP N/A
- Revenue Growth
- LPTX N/A
- NTIP N/A
- 52 Week Low
- LPTX $0.22
- NTIP $1.16
- 52 Week High
- LPTX $4.24
- NTIP $1.90
- Technical
- Relative Strength Index (RSI)
- LPTX 42.80
- NTIP 48.82
- Support Level
- LPTX $0.43
- NTIP $1.48
- Resistance Level
- LPTX $0.56
- NTIP $1.58
- Average True Range (ATR)
- LPTX 0.06
- NTIP 0.05
- MACD
- LPTX -0.02
- NTIP -0.00
- Stochastic Oscillator
- LPTX 0.04
- NTIP 29.90
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.